Edwards Lifesciences's results for Q3 2026 (ended Sep 30, 2026) come from the company's own earnings release, filed with the SEC on 2026-11-04. Everything below is taken from that filing; quotes are copied exactly. Company outlooks are the company's own.
At a glance
| Item | Value |
|---|---|
| Revenue (GAAP) | $1,716 million (+10.5% vs a year earlier) |
| Diluted EPS (GAAP) | $0.53 |
| Adjusted per-share figure (company's non-GAAP measure; FFO/AFFO for REITs) | $0.80 |
| Full-year guidance | Raised |
Guidance
Raised 2026 sales growth to ~11.5% (from 10%–11%), TAVR growth to 9%–9.5%, TMTT sales to $780–$790 million, adjusted EPS to $2.97–$3.05.
Why this label: Increasing FY2026 sales growth to ~11.5% from 10-11% and adjusted EPS to $2.97-3.05 from $2.95-3.05; nothing core lower.
| Metric | Period | New | Prior (as stated in the release) |
|---|---|---|---|
| total company sales growth (constant currency) | FY2026 | approximately 11.5% | 10%–11% |
| TAVR sales growth | FY2026 | 9%–9.5% | 8%–9% |
| TMTT sales | FY2026 | $780–$790 million | $760–$780 million |
| adjusted EPS | FY2026 | $2.97–$3.05 | $2.95–$3.05 |
| Surgical sales growth | FY2026 | mid-single-digit | mid-single-digit |
| adjusted operating profit margin | FY2026 | high end of 28%–29% | 28%–29% |
Next-quarter outlook:
| Metric | Period | Range |
|---|---|---|
| total sales | Q4 2026 | $1.67–$1.75 billion |
| adjusted EPS | Q4 2026 | $0.61–$0.69 |
From the release
Revenue: "Net sales · $ · 1,715.5 · $ · 1,553.1"
Earnings per share: "Q3 EPS of $0.53 1 ; adjusted 2 EPS of $0.80 1 which grew 19% versus prior year"
total company sales growth (constant currency): "Edwards is increasing its full-year 2026 sales growth rate guidance to approximately 11.5% from 10% to 11%"
TAVR sales growth: "TAVR product group sales growth guidance to 9% to 9.5% from 8% to 9%"
TMTT sales: "Edwards is increasing TMTT product group sales guidance to $780 to $790 million from $760 to $780 million"
Quotes are copied from the filing; in table rows, cell borders are shown as “·”.
Key fact: Raised 2026 sales growth guidance to about 11.5%; TMTT sales up 44% to $207 million.
Source
Edwards Lifesciences earnings release (SEC filing), accession 0001099800-26-000053, filed 2026-11-04.
Part of the Q3 2026 Guidance Tracker. Educational only, not advice. Free weekly recap every Sunday: yieldterminalpro.com/newsletter.